Skip to main content

Relapse/Recurrence clinical trials at UCLA

1 research study open to eligible people

Showing trials for
  • LYL797 in Adults With Solid Tumors

    open to eligible people ages 18 years and up

    This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the next part of the study, and will enroll TNBC and NSCLC patients. The second part of the study will test that dose in additional TNBC and NSCLC patients.

    Santa Monica, California and other locations

Last updated: